Topigen Pharmaceuticals Initiates European Phase 2 Clinical Study Of TPI ASM8 In Patients With Asthma

TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced the initiation of patient dosing in clinical protocol TPI ASM8-205, a Phase 2 safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8.

More: continued here

Filed under: Respiratory on February 7th, 2008